# Cetuximab in Treating Patients With Recurrent or Stage IIIB or Stage IV Lung Cancer

> **NCT00103207** · PHASE2 · COMPLETED · sponsor: **Eastern Cooperative Oncology Group** · enrollment: 72 (actual)

## Conditions studied

- Lung Cancer

## Interventions

- **BIOLOGICAL:** cetuximab

## Key facts

- **NCT ID:** NCT00103207
- **Lead sponsor:** Eastern Cooperative Oncology Group
- **Sponsor class:** NETWORK
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-10-13
- **Primary completion:** 2010-04
- **Final completion:** 2012-08
- **Target enrollment:** 72 (ACTUAL)
- **Last updated:** 2023-06-28

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00103207

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00103207, "Cetuximab in Treating Patients With Recurrent or Stage IIIB or Stage IV Lung Cancer". Retrieved via AI Analytics 2026-07-19 from https://api.ai-analytics.org/clinical/NCT00103207. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*